TRPM2 has been identified as a promising drug target in diseases of the central nervous system, such as neuropathic pain, bipolar disorder and Alzheimer’s disease, and more potential inhibitors are expected to be identified. The gene discussed is TRPM2; the disease is early-onset autosomal dominant Alzheimer disease.